Ovarian squamous cell carcinoma [SCC] is a rare and aggressive malignancy that can mimic benign gynecological disorders, often leading to diagnostic delays and suboptimal management. Ureteral obstruction and subsequent hydroureteronephrosis …
Background/Objectives: Endometriosis is a benign condition affecting up to 10% of women at reproductive age. The urinary tract is affected in 0.3-12.0% of women with endometriosis and in 19.0-53.0% of …
Glanzmann thrombasthenia (GT) is a rare haematological disorder with abnormal platelet surface receptor glycoprotein IIb/IIIa, resulting in faulty platelet aggregation. Patients with GT may present with spontaneous bleeding after trauma …
Curcumol (Cur) has been found to be useful in improving Endometriosis (EMS), however its mechanism of action is still not completely understood. Based on this, the current study was carried …
Endometriosis, while prevalent, can manifest in extra-pelvic locations with varying degrees of rarity, but reports of multiple extra-pelvic sites within a patient are extremely rare. We report a unique case …
Endometriosis presents as endometrial tissue growths outside the uterine cavity with its major symptoms including dysmenorrhea and infertility. Progestin preparations, such as dienogest, are the first-line therapy for endometriosis symptoms, …
Endometriosis and ovarian endometrioma (OMA) cause dysmenorrhea and infertility. Current hormonal therapies for OMA treatment, may exhibit limited effectiveness. Hormonal treatments function by downregulate estrogen receptors (ERs) via progesterone receptor …
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …
Endometriosis (EMS) is a prevalent gynecological disease that leads to chronic pelvic pain and infertility in women of reproductive age. However, the underlying pathogenic genes and effective treatment for EMS …
This project developed eligibility criteria for menopausal hormone therapy in patients with medical conditions beyond those published in a previous report. A new consortium of scientific societies coordinated by the …